Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06593665 · ClinicalTrials.gov registry record · Phase 3

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

A Phase 3 study of Testicular Cancer, sponsored by Indiana University.

Recruiting
Registry status
Phase 3
Development phase
142
Enrollment target
2
Study locations

NCT06593665 is a Phase 3 study of Testicular Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 142 participants, above the 82-participant average among 11 other Testicular Cancer trials with a reported enrollment target (73% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06593665, a Phase 3 study of Testicular Cancer, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
Phase 3
Development phase
142 participants
Enrollment target
2
Study locations

Study Summary

This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at different postoperative time intervals.

Conditions Studied

Interventions

  • DRUG Inrathecal Morphine
  • DRUG Intravenous Methadone

Study Locations (2)

Indiana

  • Indiana Univeristy - Indianapolis
  • Indiana University Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 142 participants
Start Date 2024-09-10
Est. Completion 2026-12-31
Phase Phase 3

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT06593665

The ClinicalTrials.gov registry entry for NCT06593665 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 11 other Testicular Cancer trials with a reported enrollment target (73% higher). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Testicular Cancer appearing as the primary indexed condition, and to 2 interventions - of which Inrathecal Morphine is the first listed.

NCT06593665 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT06593665 about?

NCT06593665 is a clinical study titled "Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.". This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at...

What is the current status of trial NCT06593665?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2024-09-10. Estimated completion is 2026-12-31.

What conditions does trial NCT06593665 study?

This clinical trial studies the following conditions: Testicular Cancer.

What interventions are being tested in trial NCT06593665?

The interventions under investigation include: Inrathecal Morphine (DRUG), Intravenous Methadone (DRUG).

Who is sponsoring clinical trial NCT06593665?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06593665 being conducted?

This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Testicular Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.